| Literature DB >> 27540436 |
John W Peabody1, David R Paculdo2, Diana Tamondong-Lachica2, Jhiedon Florentino2, Othman Ouenes2, Riti Shimkhada2, Lisa DeMaria2, Trever B Burgon2.
Abstract
BACKGROUND: Poor clinical outcomes are caused by multiple factors such as disease progression, patient behavior, and structural elements of care. One other important factor that affects outcome is the quality of care delivered by a provider at the bedside. Guidelines and pathways have been developed with the promise of advancing evidence-based practice. Yet, these alone have shown mixed results or fallen short in increasing adherence to quality of care. Thus, effective, novel tools are required for sustainable practice change and raising the quality of care.Entities:
Keywords: Clinical oncology; Evidence-based medicine; Medical education; Patient vignettes; Quality of care; Simulated patients
Year: 2016 PMID: 27540436 PMCID: PMC4974832 DOI: 10.14740/jocmr2620w
Source DB: PubMed Journal: J Clin Med Res ISSN: 1918-3003
List of CPV Cases
| Set A | Set B |
|---|---|
| Atypical ductal hyperplasia | Atypical ductal hyperplasia |
| Invasive ductal CA, stage I | Invasive ductal CA, stage I |
| Invasive lobular CA, stage II CHF | Invasive lobular CA, stage II CHF |
| Invasive ductal CA, stage II | Invasive ductal CA, stage IIB in pregnancy |
| Invasive ductal CA, stage III | Invasive ductal CA, stage III |
| Recurrent stage IIIB with bone metastasis | Recurrent stage IIIB with solitary CNS metastasis |
| Recurrent stage II invasive ductal CA | Isolated axillary recurrence, invasive ductal CA |
| Stage IIIB with recurrent disease to brain, liver | Local recurrence of stage IIIB invasive ductal CA |
| Multifocal breast cancer, stage II | Bilateral breast CA, stage IIIA (left), stage I (right) |
| Diffuse large B cell NHL, stage IIIAE. No breast CA | Ductal carcinoma |
| Hyperparathyroidism from adenoma. No progression of breast CA | Inflammatory breast CA stage IIIB |
| Dense breasts | Primary stage IV breast CA with bone metastasis |
Figure 1Example feedback form.
Provider Characteristics, Overall and by Site
| Overall | Site 1 | Site 2 | Site 3 | Site 4 | |
|---|---|---|---|---|---|
| N | 81 | 31 | 22 | 18 | 10 |
| Average age (years) | 46.4 | 47.5 | 45.0 | 45.6 | 47.6 |
| Provider type | |||||
| Medical oncologist | 34 | 7 | 12 | 7 | 8 |
| Radiation oncologist | 11 | 3 | 6 | - | 2 |
| Surgeon | 13 | 6 | 2 | 5 | - |
| Other (other MD, PharmD) | 10 | 10 | - | - | - |
| APP (PA, APRN) | 13 | 5 | 2 | 6 | - |
| Breast cancer patients (%) | 46.4 | 47.0 | 29.1 | 83.4 | 16.0 |
| Time spent teaching (%) | 14.2 | 18.2 | 12.0 | 17.2 | 1.5 |
| Average years of experience | 11.6 | 10.8 | 11.4 | 12.0 | 13.7 |
| Average case load per week (all) | 20.6 | 21.4 | 13.2 | 33.6 | 10.8 |
Figure 2Round 1 overall CPV score for all provider sites.
Average Overall and Domain CPV Scores and Standard Deviation (SD) at Baseline and Subsequent Rounds
| Baseline | Round | P-value | |||
|---|---|---|---|---|---|
| 2 | 3 | 4 | Round 4 vs. baseline | ||
| Number of CPVs | 149 | 151 | 149 | 130 | |
| Overall score | 56.6 (12.6) | 60.0 (14.4) | 69.2 (13.2) | 70.5 (16.8) | < 0.01 |
| Domain score | |||||
| History | 69.5 (13.1) | 70.9 (15.7) | 80.5 (16.8) | 85.4 (15.0) | < 0.01 |
| Physical | 83.1 (20.6) | 81.5 (21.8) | 89.4 (18.9) | 84.8 (19.9) | < 0.01 |
| Workup | 40.0 (20.8) | 48.9 (22.3) | 57.7 (24.1) | 63.4 (20.6) | < 0.01 |
| Diagnosis-treatment | 45.6 (20.8) | 51.4 (20.7) | 61.9 (19.5) | 57.6 (18.6) | < 0.01 |
Comparison of Baseline to Latest Round of CPV Scores by Areas of Care
| Area of care | Site 1 | Site 2 | Site 3 | Site 4 | ||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Round 4 | Baseline | Round 4 | Baseline | Round 4 | Baseline | Round 4 | |
| Surgery | 85% | 81% | 52% | 74% | 40% | 83% | 69% | 80% |
| Axillary management | 62% | 81% | 39% | 32% | 50% | 67% | 31% | 80% |
| Radiation therapy | 58% | 65% | 57% | 73% | 50% | 100% | 83% | 50% |
| Chemotherapy | 38% | 77% | 50% | 31% | 50% | 75% | 40% | 42% |
| Hormonal therapy | 60% | 81% | 71% | 72% | 60% | 75% | 79% | 67% |